INTRODUCTION
The depression of cell-mediated immnunity, demonstrated by various in vivo and in vitro assays, is known to be associated with malignancy (1, 2) . Patients with lung cancer have been shown to have impairment of lymphoproliferative response to mitogens and alloantigens (3, 4) . Some of these defects appear to be due to the presence of suppressor cells in the circulation (5) (6) (7) (8) . These findings suggest that immunoregulatory functions might be disturbed in cancer patients.
There is increasing evidence that a subpopulation of human non-T cells stimulates the proliferation of autologous T cells in the autologous mixed lymphocyte reaction (AMLR)' (9, 10) . Although the biologic significance of this phenomenon is not yet clarified, the reaction can be demonstrated reproducibly in normal individuals and exhibits immunologic memory and specificity (11) . The AMLR has been demonstrated to represent a natural defense mechanism against neoplastic transformation (12) , to provide a proliferative stimulus for the generation of cytotoxic lymphocytes (11) , and to regulate various immunologic functions such as production of antibody by B cells (13) and T cell response to mitogens and antigens (14, 15) . Although there is general agreement that the responding population in the AMLR is T cells, the nature of the stimulator cells has been reported variously as B cells (10) , null cells (16) , and monocytes (17) . It has recently been demonstrated that a subset of T cells that can form rosettes with autologous erythrocytes is involved in the AMLR (18, 19) and concanavalin A-induced suppressor cell function (18) .
The impairment of AMLR has been documented in patients with systemic lupus erythematosus (20, 21) , chronic lymphocytic leukemia (22) , Hodgkin's disease (23) , and Sj6gren's syndrome (24) . It is difficult to know which cell population is responsible for the depression of AMLR because both responding and stimulating cells are from the same patients and therefore T cells and non-T cells from healthy individuals with HLA-A, B, and DR locus identical to each patients' are required for exact determination. Our Autologous mixed lymphocyte cultures. Autologous mixed lymphocyte cultures were performed in triplicate using flatbottomed microtiter plates (Falcon Labware) with 1 X 105 responder T cells and 1 X 105 mitomycin C-treated (50 ug/ ml for 30 min) stimulator non-T cells in a total volume of 0.2 ml, as described (18) . Culture medium consisted of RPMI 1640 supplemented with 25 mM Hepes, 2 mM L-glutamine, 100 U penicillin/ml, 100 jig streptomycin/ml and heat-inactivated human AB serum. Cultures were incubated for 144 h at 37°C in a humidified atmosphere of 5% CO2 in air. Autorosette-forming cells. After mononuclear cells were isolated from the peripheral blood (see above), the remaining erythrocytes were collected, washed three times in phosphate-bufferred saline, and resuspended in RPMI 1640 into 1% cell suspension as described (18) . Mononuclear cells at a concentration of 2 X 106/ml in 0.1 ml RPMI 1640 were mixed with the same volume of autologous erythrocytes suspension and 0.2 ml human AB serum. The mixture was incubated for 10 min at 37°C, then centrifuged for 5 min at 200 g, and further incubated for 2 h at 4°C. The cell pellet was then gently resuspended, and one drop of the cell suspension was placed in a hemocytometer chamber, and >200 lymphocytes were counted under a microscopic examination. The percentage of lymphocytes forming rosettes with three or more erythrocytes was calculated.
To separate the autorosette-forming cells and nonrosetting cells, the autorosettes (see above) in 2 ml RPMI 1640 supplemented with 50% human AB serum were incubated for 18 h at 4°C, then gently resuspended and layered on a FicollHypaque gradient as described (18) . After centrifugation at 400 g for 30 min, the autorosette-forming cells were collected from the pellet, gently resuspended in cold RPMI 1640, and purified by another Ficoll-Hypaque centrifugation. The cell pellet was resuspended in warm RPMI 1640, incubated for 15 min at 37°C, and then vortexed to disrupt the autorosettes. The cell suspension was layered on a warm Ficoll-Hypaque gradient and centrifuged for 15 min at 400 g to eliminate the autologous erythrocytes. The cell suspension collected from the interface contained 75-97% autorosette-forming cells.
RESULTS
AMLR in peripheral blood and pleural effusion.
The AMLR between T cells and non-T cells were studied in the peripheral blood of 20 normal donors, in the peripheral blood and carcinomatous pleural effusions of 20 patients with lung cancer, and in nonmalignant pleural effusions of 8 patients with congestive heart failure ( Fig. 1 ). Blood T cells from normal controls vigorously responded to autologous non-T cells with Culture (day) 7 (Table II) . The blood T cell populations were also found not to contain suppressor cells for AMLR as described above. These results suggest that the impairment of blood AMLR of cancer patients is not attributable to the presence of suppressor cells in their circulation.
Role of autorosette-forming cells in AMLR. As lymphocytes forming rosettes with autologous erythrocytes have been shown to respond in AMLR (18, 19) , the frequency of autorosette-forming cells in the responding T cell population was determined. The number of blood T cells binding autologous erythrocytes from cancer patients averaged 16±9%, which was significantly lower (P < 0.001) than that of normal controls (31±11%). In contrast, the percentage of autorosette-forming cells of effusion T cells (34±12%) was (Fig. 3) . No significant differences were observed in the response indices of 8- 7.
6- blood lymphocytes from normal donors and blood and effusion lymphocytes from cancer patients, while tritiated thymidine incorporation by T cells was significantly lower in the blood of cancer patients than in the blood of normal donors and in the effusions of the patients. These results suggest that the depression of blood AMLR of cancer patients results from the reduction of number of T cells forming rosettes with autologous erythrocytes. To confirm the above suggestion, autorosette-forming cells were purified by density gradient centrifugation and cultured for 6 d with the same number of autologous non-T cells (Table III) . The cell population enriched for autorosette-forming cells vigorously responded in the AMLR. There was no significant difference in tritiated thymidine incorporation by autorosette-forming cells from the peripheral blood of normal donors and from the peripheral blood and pleural effusions of cancer patients, while tritiated thymidine incorporation by blood T cells of cancer patients was depressed. DISCUSSION This paper has demonstrated that T cells from the peripheral blood of patients with advanced lung cancer poorly respond to autologous non-T cells while T cells from carcinomatous pleural effusions of the same patients vigorously proliferate in response to autologous non-T cells. The impaired blood AMLR of cancer patients seems to be derived from the disease itself because the patients had no previous history of anticancer chemotherapy or radiation therapy at the time of the study and were <50 yr old. Similarly, pronounced depression of AMLR has been reported in the peripheral blood of patients with systemic lupus erythematosus (20, 21) , chronic lymphocytic leukemia (22), Hodgkin's disease (23) , infectious mononucleosis (28) , and Sj6gren's syndrome (24) . (21) , and the impaired AMLR in patients with Hodgkin's disease is due to the responder T cell population in two cases (23) . However (29) .
It has recently been demonstrated that T cells forming rosettes with autologous erythrocytes proliferate in response to autologous non-T cells in AMLR (18, 19, 30 This study has demonstrated that the AMLR in carcinomatous pleural effusions is comparable to or even higher than that in the peripheral blood of normal controls and that in nonmalignant pleural effusions of patients with congestive heart failure. Normal or higher levels of AMLR in malignant effusions is unlikely to be due to the contamination of tumor cells in the stimulator non-T cell population because effusion T cells responded to autologous blood non-T cells as strongly as to autologous effusion non-T cells. In addition, the frequency of autorosette-forming cells in the responder T cell population of pleural effusions of cancer patients was higher than that of their peripheral blood and similar to, or higher than that of normal donors. Furthermore, in patients with advanced lung cancer effusion, T cells have been shown to be able to mediate suppressor function after activation with concanavalin A, whereas blood T cells are not (26) . These findings are in keeping with previous reports that T cells capable of responding to autologous non-T cells are enriched in T cells capable of proliferating (24) and developing suppressor activity in response to concanavalin A (15, 18) .
It has been demonstrated that the AMLR provides a proliferative stimulus for the generation of cytotoxic T cells (11, 30) and represents a defense mechanism against neoplastic transformation (12) . Although the actual biological significance of the phenomenon is unclear, it may be important in host resistance against autologous tumor cells. The most potent antitumor activity may logically be expected to be present within or around the site of tumor growth. Therefore, it seems likely that the high AMLR in carcinomatous pleural effusions and low AMLR in the peripheral blood of cancer patients result from the migration of autoreactive T cells from the circulation into the site of tumor growth.
